Sunshine Biopharma (SBFM) Cash & Equivalents (2010 - 2026)

Sunshine Biopharma (SBFM) has 16 years of Cash & Equivalents data on file, last reported at $6.9 million in Q1 2026.

• Quarterly Cash & Equivalents fell 14.91% year-over-year to $6.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.9 million (down 14.91% YoY) and the FY2025 annual result came in at $9.1 million, down 5.81% from the prior year.
• Cash & Equivalents declined to $6.9 million in Q1 2026, from $9.1 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $41.7 million in Q2 2022 to a low of $6.9 million in Q1 2026.
• A 5-year average of $16.8 million and a median of $13.2 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents surged 2304.93% — and 2023, when it sank 53.53%.
• Tracing SBFM's Cash & Equivalents over 5 years: stood at $21.8 million in 2022, then dropped by 25.35% to $16.3 million in 2023, then plunged by 40.55% to $9.7 million in 2024, then decreased by 5.81% to $9.1 million in 2025, then retreated by 24.23% to $6.9 million in 2026.
• The last three Cash & Equivalents figures came in at $6.9 million (Q1 2026), $9.1 million (Q4 2025), and $9.3 million (Q3 2025), per Business Quant data.